OPAT PUBLICATIONS
International consensus recommendations for the use of prolonged-infusion beta-lactam antibiotics: Endorsed by the American College of Clinical Pharmacy, British Society for Antimicrobial Chemotherapy, Cystic Fibrosis Foundation, European Society of Clinical Microbiology and Infectious Diseases, Infectious Diseases Society of America, Society of Critical Care Medicine, and Society of Infectious Diseases Pharmacists. Endorsed by the American College of Clinical Pharmacy (ACCP), the British Society for Antimicrobial Chemotherapy (BSAC), the Cystic Fibrosis Foundation (CFF), the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), the Infectious Diseases Society of America (IDSA), the Society of Critical Care Medicine (SCCM), and the Society of Infectious Diseases Pharmacists (SIDP).
Outpatient parenteral antimicrobial therapy (OPAT) in the UK: findings from the BSAC National Outcomes Registry (2015–19). BSAC publication on data collected from its OPAT National Outcomes Registry System (NORS). This report demonstrates the safety, breadth and complexity of modern UK OPAT practice.
OPAT versus inpatient care in the UK: a health economic assessment for six key diagnoses.
BSAC & Scottish Health Technologies Group (SHTG) recommendations. BSAC and the Scottish Antimicrobial Prescribing Group (SAPG) invited SHTG to review the use of OPAT in Scotland. BSAC is pleased to endorse findings and recommendations published by Health Improvement Scotland.
How is income generated by OPAT in the UK? Analysis of payment tariffs for cellulitis.
DRUG STABILITY
PUBLISHED MANUSCRIPTS
Evaluation of the stability of aciclovir in elastomeric infusion devices used for outpatient parenteral antimicrobial therapy.
Authors: Fekade Bruck Sime, Steven Wallis, Conor Jamieson, Tim Hills, Mark Gilchrist, Mark Santillo, R Andrew Seaton, Felicity Drummond, Jason Roberts.
Journal: European Journal of Hospital Pharmacy online (doi:10.1136/ejhpharm-2023-003784).
Aciclovir full study report: Evaluation of the stability of aciclovir in elastomeric infusion devices used for Outpatient Parenteral Antimicrobial Therapy in accordance with the requirement of the UK NHS Yellow Cover Document.
Evaluation of the stability of temocillin in elastomeric infusion devices used for outpatient parenteral antimicrobial therapy in accordance with the requirements of the UK NHS Yellow Cover Document.
Authors: Fekade Bruck Sime, Steven Wallis, Conor Jamieson, Tim Hills, Mark Gilchrist, Mark Santillo, R Andrew Seaton, Felicity Drummond, Jason Roberts.
Journal: European Journal of Hospital Pharmacy online (http://dx.doi.org/10.1136/ejhpharm-2022-003286).
Temocillin full study report: Evaluation of the stability of temocillin in elastomeric infusion devices used for Outpatient Parenteral Antimicrobial Therapy in accordance with the requirement of the UK NHS Yellow Cover Document.
Assessment of ceftolozane/tazobactam stability in elastomeric devices and suitability for continuous infusion via outpatient parenteral antimicrobial therapy.
Authors: Conor Jamieson, Felicity Drummond, Tim Hills, Laima Ozolina, Mark Gilchrist, R Andrew Seaton, Mark Santillo, Alan-Shaun Wilkinson, Michael C Allwood.
Journal: JAC-Antimicrobial Resistance, Volume 3, Issue 3, September 2021 (https://doi.org/10.1093/jacamr/dlab141).
Assessment of the stability of citrate-buffered piperacillin/tazobactam for continuous infusion when stored in two commercially available elastomeric devices for outpatient parenteral antimicrobial chemotherapy: a study compliant with the NHS Yellow Cover Document requirements.
Authors: Conor Jamieson, Laima Ozolina, R Andrew Seaton, Mark Gilchrist, Tim Hills, Felicity Drummond, Alan-Shaun Wilkinson, on behalf of the BSAC Drug Stability Testing Working Group.
Journal: European Journal of Hospital Pharmacy online (http:// dx. doi. org/ 10. 1136/ ejhpharm- 2020- 002340).
Investigation of meropenem stability after reconstitution: the influence of buffering and challenges to meet the NHS Yellow Cover Document compliance for continuous infusions in an outpatient setting.
Authors: Conor Jamieson, Michael Charles Allwood, Donata Stonkute, Andrew Wallace, Alan-Shaun Wilkinson, Tim Hills, on behalf of the BSAC Drug Stability Working Party.
Journal: European Journal of Hospital Pharmacy, 2018;0:1–5. doi:10.1136/ejhpharm-2018-001699.
Assessment of the stability of citrate-buffered flucloxacillin for injection when stored in two commercially available ambulatory elastomeric devices: INfusor LV (Baxter) and Accufuser (Woo Young Medical): a study compliant with the NHS Yellow Cover Document (YCD) requirements.
Authors: Michael Charles Allwood, Donata Stonkute, Andrew Wallace, Alan-Shaun Wilkinson, Tim Hills, and Conor Jamieson on behalf of the BSAC Drug Stability Working Party.
Journal: European Journal of Hospital Pharmacy, 2018. 0:1–5. doi:10.1136/ejhpharm-2018-001515.
Extended stability of antimicrobial agents in administration devices
Author: Abi Jenkins; Tim Hills; Mark Santillo; Mark Gilchrist;
Journal: Journal of Antimicrobial Chemotherapy, 2017; doi: 10.1093/jac/dkw556.
POSTERS:
Presented at ECCMID, April 2022
Aciclovir Poster
Title: Evaluation of the stability of aciclovir in elastomeric infusion devices used for outpatient parenteral antimicrobial therapy (OPAT) services in accordance with the requirements of the UK NHS Yellow Cover Document.
Authors: Fekade B. Sime, Steven C. Wallis, Conor Jamieson, Tim Hills, Mark Gilchrist, Mark Santillo, R. Andrew Seaton, Felicity Drummond, Jason A. Roberts
Amoxicillin Poster
Title: Scoping the stability of amoxicillin for use in Outpatient Parenteral Antimicrobial Therapy (OPAT) services in accordance with the requirements of the UK NHS Yellow Cover Document.
Authors: Fekade B. Sime, Steven C. Wallis, Conor Jamieson, Tim Hills, Mark Gilchrist, Mark Santillo, R. Andrew Seaton, Felicity Drummond, Jason A. Roberts
Presented at the BSAC OPAT Conference, 11th December 2019
Piperacillin/tazobactam
Title: Assessing the stability of piperacillin/tazobactam at 25 mg/mL and 90 mg/mL reconstituted and diluted in 0.3% w/v citrate buffered saline in two commercially available elastomeric devices.
Authors: Conor Jamieson, Felicity Drummond, Laima Ozolina and Alan-Shaun Wilkinson, on behalf of the UK OPAT Initiative Drug and Stability Working Group.
Cefatzidime
Title: Stability testing of ceftazidime solutions for injection in elastomeric devices at 12 mg/mL and 25 mg/mL in 0.9% w/v saline for safe use in Outpatient Parenteral Antimicrobial Therapy (OPAT).
Authors: Conor Jamieson, Felicity Drummond, Laima Ozolina and Alan-Shaun Wilkinson, on behalf of the UK OPAT Initiative Drug and Stability Working Group.
Ceftolozane/tazobactam
Title: Assessing the stability of ceftolozane/tazobactam (ZERBAXA®) at 5 mg/mL and 20 mg/mL following reconstitution and dilution in 0.9% saline in two commercially available elastomeric devices.
Authors: Conor Jamieson, Felicity Drummond, Laima Ozolina and Alan-Shaun Wilkinson, on behalf of the UK OPAT Initiative Drug and Stability Working Group.
Presented at the BSAC OPAT Conference, 13th-14th December 2018
OPAT flow rate
Title: Outcomes of a National Survey of Experience with Continuous Infusion Elastomeric Devices in OPAT.
Authors: Tim Hills, Conor Jamieson, Mark Gilchrist, Carolyne Horner, Andrew Seaton, on behalf of the UK OPAT Initiative Drug and Stability Working Group.
Presented at the BSAC OPAT Conference, 11th-12th December 2017
Flucloxacillin
Title: Assessment of the stability of citrate-buffered Flucloxacillin for injection when stored in two commercially available ambulatory devices: INfusor (Baxter) and Accufuser® (Woo Young Medical), a study compliant with the NHS Yellow Cover Document (YCD) requirements.
Authors: Tim Hills MRPharmS Michael Charles Allwood PhD, Donata Stonkute BSc, Andrew Wallace PhD, Alan-Shaun Wilkinson PhD, on behalf of the BSAC Drug Stability Working Party.
Meropenem
Title: The influence of pH and buffering on the stability of Meropenem 6.25-25 mg/ml at 32C.
Authors: Tim Hills MRPharmS Michael Charles Allwood PhD, Donata Stonkute BSc, Andrew Wallace PhD, Alan-Shaun Wilkinson PhD, on behalf of the BSAC Drug Stability Working Party.
DOCUMENT: OPAT Guidance
Title: Guidance on the pharmaceutical issues concerning OPAT Services and other outpatient intravenous therapies.
Authors: Mark Santillo, Abi Jenkins, Conor Jamieson on behalf of the NHS Pharmaceutical Quality Assurance Committee.
GOOD PRACTICE RECOMMENDATIONS
Updated good practice recommendations for outpatient parenteral antimicrobial therapy (OPAT) in adults and children in the UK (Full recommendations)
Leader Article in JAC: Outpatient parenteral antimicrobial therapy: updated recommendations from the UK
An assessment tool has been provided for you to assess your OPAT service against the updated Good Practice Recommendations. The tool is provided as an Excel Survey Tool (to be completed electronically) and as a PDF (for printing and information only).
BSAC are interested in your thoughts about the updated OPAT Good Practice Recommendations. Watch this space for news of a survey that will collect thoughts and experiences.
Earlier versions of the OPAT Good Practice Recommendations
Good practice recommendations for Outpatient Parenteral Antimicrobial Therapy (OPAT) in adults in the UK: a consensus statement
PAEDIATRIC SUPPORT RESOURCES
The following resources are reproduced with the kind permission of Southampton Children’s Hospital OPAT Service:
Parent-carer-PICC-guidance
Infusion-Aseptic-No-Touch-technique
Parent-carer-CVC-guidance
Hand-washing-technique
Ground-rules-for-parents-carers
Competency-checklist-for-parents-carers
Community-Nurse-Template
Cribb-sheet-for-registrars
Bolus-dose-Aseptic-No-Touch-Technique
The following resources are reproduced with the kind permission of Bradford Teaching Hospitals Paediatric OPAT Service:
Ambulation referral form
Care Bundle including parent contract
Crib sheet
Discharge checklist
Full Capacity Protocol
Paediatric OPAT delivery service SOP
Unable to Contact Protocol volume 1
Visit documentation
Your Child’s Home Intravenous Antibiotic Treatment Plan leaflet
Inclusion of the above resources does not imply BSAC endorsement or approval.
